Cerus Co. (NASDAQ:CERS - Get Free Report) insider Richard J. Benjamin sold 18,949 shares of the firm's stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $1.45, for a total value of $27,476.05. Following the completion of the transaction, the insider now owns 715,850 shares in the company, valued at $1,037,982.50. This represents a 2.58 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Cerus Stock Up 0.3 %
Shares of CERS traded up $0.01 during midday trading on Friday, hitting $1.54. The stock had a trading volume of 667,783 shares, compared to its average volume of 1,226,499. The company has a debt-to-equity ratio of 1.19, a current ratio of 2.59 and a quick ratio of 1.92. The firm has a market cap of $285.19 million, a price-to-earnings ratio of -14.02 and a beta of 1.56. The company has a 50 day simple moving average of $1.71 and a two-hundred day simple moving average of $1.75. Cerus Co. has a twelve month low of $1.38 and a twelve month high of $2.54.
Cerus (NASDAQ:CERS - Get Free Report) last released its earnings results on Thursday, February 20th. The biotechnology company reported ($0.01) EPS for the quarter, meeting the consensus estimate of ($0.01). Cerus had a negative return on equity of 40.55% and a negative net margin of 11.60%. The firm had revenue of $50.81 million for the quarter, compared to analysts' expectations of $50.81 million. On average, analysts anticipate that Cerus Co. will post -0.08 EPS for the current year.
Wall Street Analyst Weigh In
Separately, Cantor Fitzgerald restated an "overweight" rating and set a $4.00 price objective on shares of Cerus in a report on Friday, February 21st.
Read Our Latest Research Report on CERS
Institutional Inflows and Outflows
A number of hedge funds have recently added to or reduced their stakes in the business. Rockport Wealth LLC acquired a new stake in shares of Cerus in the fourth quarter valued at about $25,000. Wealth Enhancement Advisory Services LLC bought a new position in Cerus in the fourth quarter valued at approximately $25,000. Cibc World Markets Corp bought a new stake in shares of Cerus during the 4th quarter worth approximately $26,000. R Squared Ltd acquired a new stake in shares of Cerus in the 4th quarter valued at approximately $29,000. Finally, Virtu Financial LLC bought a new position in shares of Cerus in the fourth quarter valued at $33,000. Institutional investors own 78.37% of the company's stock.
Cerus Company Profile
(
Get Free Report)
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
Read More
Before you consider Cerus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cerus wasn't on the list.
While Cerus currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
